Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Jan;12(1):56-60.
doi: 10.2450/2013.0013-13. Epub 2013 Nov 15.

Prevalence, specificity and risk of red blood cell alloantibodies among hospitalised Hubei Han Chinese patients

Affiliations
Clinical Trial

Prevalence, specificity and risk of red blood cell alloantibodies among hospitalised Hubei Han Chinese patients

Pu Xu et al. Blood Transfus. 2014 Jan.

Abstract

Background: The prevalence, specificity and risk of red blood cell alloantibodies vary widely among different geographic areas, races, and diseases and according to different methods of study, but no data are available on the Chinese Han population, who were investigated in the present study.

Materials and methods: Antibody screening was conducted among 42,517 hospitalised Hubei Han Chinese individuals using column agglutination technology. Samples that were positive in antibody screening were subjected to antibody identification by the tube test. Clinical data, including gender, age, race, transfusion history and records of alloantibody detection, transfusion reactions or haemolytic disease of the newborn, were collected to analyse the prevalence and specificity of alloantibodies and complications associated with them.

Results: A total of 212 patients with alloantibodies were identified among 42,517 patients, yielding a prevalence of 0.50% in this study. Significantly different prevalence rates were observed according to age and sex. The most frequently identified alloantibodies were anti-E (87/212, 41.0%), anti-D (45/212, 21.2%), anti-M (41/212, 19.3%) and a combination of anti-E and anti-c (13/212, 6.1%). Haemolytic disease was observed in 13 infants with anti-D, three infants with anti-E and one infant with anti-Fy(a) alloantibodies. Delayed haemolytic transfusion reactions occurred in four patients with alloantibodies.

Discussion: In hospitalised Hubei Han Chinese individuals, the overall prevalence of alloantibodies was 0.50%, with anti-E, anti-D and anti-M being the most frequently identified alloantibodies. These results indicate that anti-D and anti-E alloantibodies were major risk factors for haemolytic disease of the newborn or delayed haemolytic transfusion reactions in this study population.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution of alloantibodies among different age groups.

Similar articles

Cited by

References

    1. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood. 2012;120:528–37. - PMC - PubMed
    1. Schonewille H, Haak HL, van Zijl AM. Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases. Transfusion. 1999;39:763–71. - PubMed
    1. Gottvall T, Filbey D. Alloimmunization in pregnancy during the years 1992–2005 in the central west region of Sweden. Acta Obstet Gynecol Scand. 2008;87:843–8. - PubMed
    1. Patel SR, Smith NH, Kapp L, Zimring JC. Mechanisms of alloimmunization and subsequent bone marrow transplantation rejection induced by platelet transfusion in a murine model. Am J Transplant. 2012;12:1102–12. - PMC - PubMed
    1. de Montalembert M, Dumont MD, Heilbronner C, et al. Delayed hemolytic transfusion reaction in children with sickle cell disease. Haematologica. 2011;96:801–7. - PMC - PubMed

Publication types

MeSH terms